NOVTTechnology · Scientific & Technical InstrumentsThe 3 Wall Street analysts covering Novanta, Inc. hold a median 12-month price target of $195 — +42.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 22 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Novanta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (95): Analysts have, on balance, been raising their forecasts.
Volatility (26): The share price moves around a lot.
Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NOVT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +42.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 May 2026 | Baird | Maintains | Outperform | $144 → $173 |
| 30 Mar 2026 | Baird | Upgrade | Outperform | — |
| 11 Aug 2025 | Baird | Maintains | Neutral | — |
| 3 Mar 2025 | Baird | Maintains | Neutral | — |
| 6 Nov 2024 | Baird | Maintains | Neutral | — |
| 7 Aug 2024 | Baird | Maintains | Neutral | — |
| 11 May 2023 | Baird | Maintains | Neutral | — |
| 11 May 2022 | William Blair | Upgrade | Outperform | — |
| 13 Nov 2020 | Berenberg | Initiates | Hold | — |
| 13 May 2020 | Baird | Maintains | Neutral | — |
| 28 Feb 2019 | Baird | Maintains | Neutral | — |
| 9 May 2018 | Baird | Downgrade | Neutral | — |
| 27 Feb 2018 | William Blair | Initiates | Outperform | — |
| 8 Dec 2017 | Baird | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NOVT appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Novanta, Inc. returned +17.3% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 8% of US stocks
Cheaper than 23% of US stocks
Cheaper than 28% of US stocks
Cheaper than 10% of US stocks
Higher than 53% of US stocks
Higher than 89% of US stocks
Higher than 56% of US stocks
Higher than 66% of US stocks
Higher than 62% of US stocks
Higher than 54% of US stocks
Higher than 71% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Novanta, Inc. has a market value of $5.3B and an enterprise value of $4.9B.
Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 10.3% year on year.
Net income over the same four quarters: $61.8M, a 6.0% net margin.
Diluted earnings per share, trailing twelve months: $1.56.
Free cash flow in the twelve months to 30 June 2026: $114.3M.
Novanta, Inc. spent $51.8M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 88.6×; forward P/E: 32.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Novanta, Inc. employs 3,000 people — $343K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Novanta, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article says high-quality real-world data remains a bottleneck in training robot hands, because video alone does not measure touch or force.
Why it matters — The topic concerns robotics and automation, areas potentially relevant to a NOVT watcher, but the excerpt provides no company-specific information.
Novanta announced that CFO Robert Buckley and John Lesica, COO of Medical Solutions, are scheduled to present at the Baird 2026 Global Industrial Conference on November 11 in Chicago.
Why it matters — NOVT watchers may note the scheduled conference appearance by two company executives.
Danaher announced plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations scheduled to begin in early 2027. The announcement reportedly had little effect on the stock on the day.
Why it matters — The development highlights growing automation in life sciences, a trend relevant to NOVT watchers, though the excerpt provides no direct information about Novanta.
Novanta will release its third-quarter 2026 results after U.S. markets close on November 9, 2026, and hold a conference call to discuss them at 8:00 a.m. ET on November 10.
Why it matters — The announcement gives NOVT watchers the dates and time for the company’s upcoming results and related discussion.
ETF Trends continues its series on constructing a humanoid, following up on an earlier breakdown of the three key build areas and a prior look at companies behind the technologies for a humanoid's brain. This installment addresses the components and firms involved in building a humanoid body.
Why it matters — A NOVT watcher would care because humanoid-construction articles highlight the technologies and supply chains tied to robotics and precision component demand, areas relevant to Novanta.
The 3 Wall Street analysts covering Novanta, Inc. have a median 12-month price target of $195, with estimates ranging from $194 to $195. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Novanta, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Novanta, Inc. 61 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Novanta, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +42.3% from the last close, and Ticker Nerd's factor model ranks Novanta, Inc. 61 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Novanta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NOVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $194 to $195 over the next 12 months.
Novanta, Inc. returned +17.3% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Novanta Inc. is a global technology company that provides core solutions for medical and advanced industrial equipment manufacturers.
The most recent item we track (ETF Trends, 21 Oct 2026): "Human Data, Robot Hands: Where Automation Goes Next". The article says high-quality real-world data remains a bottleneck in training robot hands, because video alone does not measure touch or force.
Novanta Inc. is a global technology company that provides core solutions for medical and advanced industrial equipment manufacturers. Novanta designs and manufactures precision photonics, vision, and motion control components and subsystems used in applications such as laser processing, robotics, automation, metrology, and scientific instrumentation. The company also supplies medical technologies for surgical imaging, visualization, identification, and other clinical workflows, supporting original equipment manufacturers across healthcare and life science markets. Novanta operates through its Automation Enabling Technologies and Medical Solutions segments, serving customers in North America, Europe, and Asia Pacific. Headquartered in Bedford, Massachusetts, Novanta focuses on mission-critical technologies that help its customers build highly specialized systems requiring precision, reliability, and performance.
CEO Mr. Matthijs Glastra · 3,000 employees · United States · https://www.novanta.com
